Gastops technology to be evaluated by Royal Canadian Navy for predictive maintenance - MRO Magazine
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Ottawa-based Gastops has secured a contract with the Government of Canada's Innovative Solutions Canada Testing Stream program to evaluate its FluidSIGHT condition-monitoring technology for the Department of National Defence and the Royal Canadian Navy. The project aims to enhance condition-based and predictive maintenance by providing real-time insights into lubricant health and equipment wear.
The FluidSIGHT system offers continuous monitoring, moving beyond traditional oil sampling methods.
This article is an excerpt. To read the full content, visit the original source. MRO Magazine
Related articles
Bringing predictive analytics to the agentic AI era - MIT Technology Review
SponsoredPredictive modeling with AI can revolutionize how organizations use everyday business data. October 5, 2026 In 2026, the question for enterprise AI is no longer whether predictive models can outperform statistical forecasts—that argument is settled. The big question now is how to enable predictive systems to act on their own conclusions without drifting from business intent. The frontier has moved from prediction to autonomous decision making, and the gap between leaders and laggards is widening accordingly. “Enterprises are done with a backward-looking point of view; they want to be more forward-thinking,” says Vishal Gupta, partner at research firm Everest Group. Intelligent analytics, powered by technologies like deep learning and generative AI, are making this possible. Real-time training allows AI to evolve continuously instead of waiting for quarterly refreshes. In addition, the data that newer predictive engines rely upon has expanded to encompass not just neat, numerical records but also messy, unstructured sources of insight-rich interactions. As a result, AI-powered analytics are moving enterprises from passive hindsight to pragmatic foresight.
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division - The Globe and Mail
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer CentersTAMPA, FL - DataMeds AI, Inc. (NASDAQ:MEDS) (“DataMeds AI,” “DataMEDS SI,” “DataMEDS,” or the “Company”), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only. ChemoFx has recently been included, for the first time, in a Humana Medicaid coverage policy for gynecologic cancers. DataMeds AI, Inc. is a B2i DigitalFeatured Company.
0 comments
No comments yet. Be the first to share your thoughts!